
National Research Corporation NRC
$ 20.43
3.6%
Quarterly report 2025-Q3
added 11-07-2025
National Research Corporation DPO Ratio 2011-2026 | NRC
Annual DPO Ratio National Research Corporation
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | 10.1 | 4.7 | 4.41 | 6.13 | 5.02 | 7.26 | 6.15 | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 10.1 | 4.41 | 6.25 |
DPO Ratio of other stocks in the Diagnostics research industry
| Issuer | DPO Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Akumin
AKU
|
21.3 | - | -17.87 % | $ 25.9 M | ||
|
Centogene N.V.
CNTG
|
120 | - | -6.23 % | $ 30.6 M | ||
|
Chembio Diagnostics
CEMI
|
52.5 | - | 0.22 % | $ 16.8 M | ||
|
Burning Rock Biotech Limited
BNR
|
125 | $ 23.45 | 0.63 % | $ 252 M | ||
|
Biocept
BIOC
|
56.3 | - | -13.05 % | $ 7.29 M | ||
|
Co-Diagnostics
CODX
|
106 | $ 5.98 | -3.39 % | $ 175 M | ||
|
Accelerate Diagnostics
AXDX
|
125 | - | -61.36 % | $ 2.46 M | ||
|
DermTech
DMTK
|
47.4 | - | -11.32 % | $ 2.94 M | ||
|
Castle Biosciences
CSTL
|
52 | $ 39.66 | 0.81 % | $ 1.1 B | ||
|
DexCom
DXCM
|
70.4 | $ 70.98 | 5.31 % | $ 27.4 B | ||
|
BioNano Genomics
BNGO
|
104 | $ 1.59 | 0.63 % | $ 2.02 M | ||
|
Oxford Immunotec Global PLC
OXFD
|
45.8 | - | - | $ 562 M | ||
|
Guardant Health
GH
|
83.6 | $ 107.57 | -2.36 % | $ 13.2 B | ||
|
Global Cord Blood Corporation
CO
|
17.7 | - | - | $ 399 M | ||
|
Fluidigm Corporation
FLDM
|
61.4 | - | 1.08 % | $ 308 M | ||
|
Genetic Technologies Limited
GENE
|
780 | - | - | $ 7.1 B | ||
|
Genetron Holdings Limited
GTH
|
43.5 | - | 0.12 % | $ 80.1 M | ||
|
Illumina
ILMN
|
56.3 | $ 145.55 | 3.18 % | $ 23.1 B | ||
|
PRA Health Sciences, Inc.
PRAH
|
8.98 | - | - | $ 10.7 B | ||
|
IQVIA Holdings
IQV
|
126 | $ 240.86 | -0.66 % | $ 43.7 B | ||
|
CareDx, Inc
CDNA
|
44.2 | $ 20.57 | 20.08 % | $ 1.11 B | ||
|
Danaher Corporation
DHR
|
66.4 | $ 239.0 | 0.27 % | $ 175 B | ||
|
DarioHealth Corp.
DRIO
|
43.9 | $ 11.67 | -4.03 % | $ 331 M | ||
|
Anixa Biosciences
ANIX
|
1.29 K | $ 3.16 | -6.51 % | $ 103 K | ||
|
Enzo Biochem
ENZ
|
52.3 | - | -8.98 % | $ 14.8 K | ||
|
Lantheus Holdings
LNTH
|
25.3 | $ 67.48 | -0.12 % | $ 4.67 B | ||
|
Exact Sciences Corporation
EXAS
|
139 | $ 102.23 | 0.12 % | $ 18.9 B | ||
|
Medpace Holdings
MEDP
|
13.3 | $ 599.21 | 0.71 % | $ 18.5 B | ||
|
Fulgent Genetics
FLGT
|
34.9 | $ 28.16 | 1.11 % | $ 851 M | ||
|
Aspira Women's Health
AWH
|
112 | - | -6.19 % | $ 10.5 M | ||
|
Motus GI Holdings
MOTS
|
1.72 | - | -34.28 % | $ 263 K | ||
|
Myriad Genetics
MYGN
|
42 | $ 6.57 | -0.15 % | $ 595 M | ||
|
Natera
NTRA
|
17.9 | $ 235.45 | 0.49 % | $ 23.2 B | ||
|
OPKO Health
OPK
|
43.1 | $ 1.33 | -2.21 % | $ 923 M | ||
|
Pacific Biosciences of California
PACB
|
33.5 | $ 2.01 | 3.61 % | $ 510 M | ||
|
Charles River Laboratories International
CRL
|
24.5 | $ 218.82 | -0.95 % | $ 11.2 B | ||
|
Heska Corporation
HSKA
|
39.7 | - | - | $ 1.31 B | ||
|
Personalis
PSNL
|
67.3 | $ 8.57 | 5.8 % | $ 508 M | ||
|
HTG Molecular Diagnostics
HTGM
|
112 | - | -20.0 % | $ 1.06 M | ||
|
Mettler-Toledo International
MTD
|
53.4 | $ 1 491.99 | 0.46 % | $ 31.7 B | ||
|
ENDRA Life Sciences
NDRA
|
1.65 K | $ 4.53 | -2.58 % | $ 2.43 M | ||
|
Invitae Corporation
NVTA
|
69 | - | - | $ 21.2 M | ||
|
Neogen Corporation
NEOG
|
62.7 | $ 9.37 | -2.6 % | $ 2.03 B | ||
|
Quest Diagnostics Incorporated
DGX
|
18.3 | $ 175.94 | 0.85 % | $ 19.5 B | ||
|
Organovo Holdings
ONVO
|
82.9 K | - | -2.3 % | $ 19.4 M |